

# Temperature, Neutrophils and Multiple Organ Failure Score: A Simple Scoring System to Predict Mortality Following Perforated Peptic Ulcer

Mario Schietroma<sup>1</sup>, Lucia Romano<sup>1\*</sup>, Sara Lazzari<sup>2</sup>, Beatrice Pessia<sup>2</sup>, Antonella Mattei<sup>3</sup>, Fabiana Fiasca<sup>3</sup>, Francesco Carlei<sup>1</sup>, Antonio Giuliani<sup>1</sup>

**\*Corresponding author:**

Lucia Romano, MD  
University of L'Aquila  
San Salvatore Hospital  
L'Aquila, Italy  
Tel: +39. 0862 368550  
Fax: +39. 0862 368550  
E-mail: lucia.romano1989@libero.it

<sup>1</sup>Department of General Surgery, University of L'Aquila, Italy

<sup>2</sup>Department of Hepato-biliopancreatic Surgery, San Salvatore Hospital, L'Aquila, Italy

<sup>3</sup>Department of Life, Health & Environmental Sciences, University of L'Aquila, Italy

## ABSTRACT

**Purposes:** Patients with perforated peptic ulcer (PPU) present with signs of sepsis and appropriate management can be offered to achieve an optimal outcome of disease. We propose evaluating the severity of intra-abdominal sepsis in case of PPU with a new score called TNM, name borrowed by cancer staging, with the aim of assess its predictive value.

**Methods:** We included 183 patients with diagnosis of complicated PPU. We defined categories T (Temperature), N (Neutrophils count) and M (MOF); then, patients were grouped in stages (0-IV). Variables analysed were age, sex, ASA, blood transfusion, causes of sepsis, temperature, neutrophils count, preoperative organ failure, immune-compromised status, stage (0-IV).

**Results:** Patients were grouped as follows: none at stage 0; 6 at stage I; 72 at stage II, 72 at stage III; 33 at stage IV. ASA score, neutrophils count, preoperative organ failure, stage III-IV emerged as statistically significant different prognostic factors. ASA score and stage were significant independent predictors of post-operative mortality in multivariate analysis.

**Conclusion:** Our proposed system could define and help to assess the mortality risk.

**Key words:** peptic ulcer, perforated peptic ulcer, intra-abdominal sepsis, localized peritonitis, generalized peritonitis, scoring systems

## INTRODUCTION

Peptic ulcer disease, both duodenal and gastric, despite the widespread availability of effective acid reduction agents and antibiotic therapy for *Helicobacter pylori* (1), is associated with potentially life-threatening complications, including bleeding, perforation, penetration and obstruction. Intra-abdominal sepsis (IAS) after perforation is the second most frequent complication after bleeding (2,3). A high risk for morbidity (20-50%) and mortality (1.3-40%) is encountered in surgically treated perforated peptic ulcer (PPU)

Received: 27.05.2021

Accepted: 28.07.2021

patients (4-9). Patients with PPU present with signs of sepsis and by a careful preoperative assessment of the patients' severity grade, appropriate management can be offered to achieve an optimal outcome of disease (10,11). Many scoring systems (Boey score, Peptic Ulcer Perforated (PULP) Score, American Society of Anaesthesiologists (ASA) score) have been proposed to predict mortality after PPU (12-14). PULP score seems to be the most reliable, but it is very complex to use (12). Boey score is easier but its predictability value is not consistent (12,15-17). ASA score is a general surgical risk score not intended for PPU patients in particular, and its major drawback is its subjective assessment (12,15). Nowadays, in the clinical practice the grading systems are not always employed for PPU, although they seem to give precise clinical indications, because some of them are too complicated (PULP score) and others are too aspecific (ASA score). In our work, we tried to assess the severity of IAS as a complication of PPU using a new TNM score: T indicates Temperature, N Neutrophil count and M Multiple organ failure (MOF) (18,19). In this study we aimed to evaluate significance of this score to predict mortality of patients with complicated PPU.

## MATERIALS AND METHODS

The TNM system was studied in 183 patients with complicated PPU and IAS, managed in General Surgery and Hepato-biliopancreatic Surgery at our Department of Surgery in the period between April 2012 and December 2019. Pregnant women, patients aged < 18, immune-compromised patients and those who underwent laparoscopic surgery were excluded.

At the presentation, patients were clinically evaluated; blood tests and imaging exams were performed. Intravenous antibiotic therapy was set up: Ciprofloxacin 200 mg or Amoxicillin-clavulanic 2 gr and Metronidazole 500 mg.

The anthropometric data were collected in an electronic database. According to clinical and laboratory characteristics, the patients were classified based on our system. *Table 1* resumes the definitions. The classes of the patients is showed in *table 2*, which also shows the groupings in stages (stage 0-IV).

For the study of this system, we used retrospective data of 102 patients between January 2001 and January 2012 (control group); the study group was prospectively evaluated. TNM stage was firstly evaluated at the time of the presentation and then every day of recovery. The primary endpoint was to assess the efficacy of TNM score in forecasting mortality at 30

**Table 1 - Definition of organ failure**

Renal	One or more the following : <ul style="list-style-type: none"> <li>• Dialysis</li> <li>• Creatinine &gt; 1.4 mg%</li> <li>• Urine output &lt; 150 ml per 8 h</li> </ul>
Respiratory	pO <sub>2</sub> < 60 mmHg
Cardiovascular	One or more the following: <ul style="list-style-type: none"> <li>• Hypotension ≤ 90 mmHg</li> <li>• Use of inotropic support :               <ul style="list-style-type: none"> <li>- Dopamine</li> <li>- Dobutamine</li> <li>- Epinephrine</li> <li>- Norepinephrine</li> </ul> </li> </ul>

days. The work has been reported in line with the STROCSS criteria (20).

### Statistical analysis

The characteristics of the study sample were analysed with descriptive statistics; the discrete and nominal variables were expressed using frequencies and percentages; for continuous variables, medians and range were reported. The frequency distribution of prognostic factors (age classes, sex, ASA score, blood transfusion, causes of sepsis, fever, neutrophil count, pre-operative organ failure, immuno-compromised status, TNM stage) were examined between outcome groups (alive or dead). Chi square ( $\chi^2$ ) test was used to analyse statistical differences. Variables significantly different between the two groups were introduced in the multivariate logistic model to obtain independent predictors of death, with associations reported as odds ratios (ORs) and 95% confidence intervals (CIs).

Model discrimination was evaluated using the receiver operating characteristics (ROC) curve. All data were electronically recorded; statistical analyses were performed using the Stata Statistical Software (Release 15/IC, College Station, TX: Stata Corp LP). All the tests were two-tailed, and  $p < 0.05$  was considered statistically significant.

## RESULTS

One hundred eighty-three consecutive patients were included; they had a mean age of 67.0 years (range 23 to 86). No significative differences of age between the sexes was reported. One hundred and seventeen patients (63.9%) were diagnosed with localized peritonitis or abscesses and sixty-six (36%) with generalized peritonitis. Distribution of patients into the stages, according to clinical findings and laboratory values, is showed in *table 3*. Death occurred

**Table 2 - Temperature- Neutrophil- Multiple organ failure (TNM) Staging System for complicated IAS\* after PPU\*\***

TNM score		
<b>Temperature (T) ***</b>	<b>Maximum daily temperature (°C) ****</b>	
T0	36.4- 37.4	
T1	37.5-38.4	
T2	38.5-39.0	
T3	39.1- 39.5	
T4	>39.5 ; <36.4	
<b>Neutrophil (N)</b>	<b>%</b>	
N0	40-74	
N1	75-85	
N2	86-90	
N3	> 90 ; < 40	
<b>Multiple organ failure (M)</b>	<b>Organ failure</b>	
M0	No organ failure	
M1	One organ failure	
M2	Two or more organ failure	
<b>Stage</b>	<b>TNM</b>	<b>Clinical Profile</b>
0	T0 N0 M0	Mild Sepsis
I		Mild Sepsis
Ia	T1; N0, N1; M0	
Ib	T2; N0, N1; M0	
II		Moderate Sepsis
IIa	T3; N0,N1,N2; M0	
IIb	T4; N0, N1, N2; M0	
III		Severe Sepsis
IIIa	any T; N3; M0	
IIIb	any T; any N; M1	
IV	any T; any N; M2	Septic Shock

\* IAS : Intra-Abdominal Sepsis, \*\*PPU: Perforated Peptic Ulcer, \*\*\*Oral temperature, \*\*\*\*Temperature should be recorded at least 4 times in 24h

in 31.2% patients, and their mean age was 59.7 years (range 23 – 74). The mean age of survivors was 66.1 years (range 45 – 86). No patient in the stage I died; mortality progressively increased among stages and reached 52.6% at the stage IV (table 3).

Statistically significant differences using  $\chi^2$  test emerged for ASA score, neutrophil count, pre-operative organ failure and TNM stage between outcome groups (table 4). As neutrophil count and pre-operative organ failure are variables that define the TNM stage, they

**Table 3 - IAS\* after PPU\*\*: Stage TNM on the day of diagnosis/admission and mortality**

Stage TNM	N° (%)	Dead N ° (%)	Alive N ° (%)	Clinical Profile
0	/	/	/	Mild Sepsis
I	6 (3.28)	/	6 (4.76)	Mild Sepsis
Ia	3 (1.64)	/	3 (2.38)	
Ib	3 (1.64)	/	3 (2.38)	
II	72 (39.34)	9 (15.79)	63 (50.00)	Moderate Sepsis
IIa	36 (19.67)	3 (5.26)	33 (26.19)	
IIb	36 (19.67)	6 (10.53)	30 (23.81)	
III	72 (39.34)	18 (31.58)	54 (42.86)	Severe Sepsis
IIIa	33 (18.03)	6 (10.53)	27 (21.43)	
IIIb	39 (21.31)	12 (21.05)	27 (21.43)	
IV	33 (18.03)	30 (52.63)	3 (2.38)	Septic Shock
Total	183	57 (31.15)	126 (68.85)	

\*IAS: Intra-Abdominal Sepsis, \*\*PPU: Perforated Peptic Ulcer

**Table 4 - Distribution of prognostic factors of death in patients with IAS\* after PPU\*\***

Prognostic factors	Total N=183	Alive n (%) 126 (68.85)	Dead n (%) 57 (31.15)	p-value
Age classes, n (%)				0.051***
< 67 years	87 (47.54)	66 (52.38)	21 (36.84)	
≥ 67 years	96 (52.46)	60 (47.62)	36 (63.16)	
Sex, n (%)				0.322***
Male	87 (47.54)	63 (50.00)	24 (42.11)	
Female	96 (52.46)	63 (50.00)	33 (57.89)	
ASA score, n (%)				<0.001***
I, II	108 (59.02)	93 (73.81)	15 (26.32)	
III, IV	75 (40.98)	33 (26.19)	42 (73.68)	
Blood transfusion, n (%)				0.485***
No	159 (86.89)	108 (85.71)	51 (89.47)	
Yes	24 (13.11)	18 (14.29)	6 (10.53)	
Causes of sepsis, n (%)				0.383***
Duodenal ulcer	105 (57.38)	75 (59.52)	30 (52.63)	
Gastric ulcer	78 (42.62)	51 (40.48)	27 (47.37)	
Fever (°C), n (%)				0.093***
37.5–38.4	24 (13.11)	18 (14.29)	6 (10.53)	
38.5–39.0	57 (31.15)	33 (26.19)	24 (42.11)	
39.1–39.5	57 (31.15)	45 (35.71)	12 (21.05)	
>39.5; <36.4	45 (24.59)	30 (23.81)	15 (26.32)	
Neutrophil count, n (%)				0.007***
40–74	27 (14.75)	24 (19.05)	3 (5.26)	
75–85	45 (24.59)	36 (28.57)	9 (15.79)	
85–90	51 (27.87)	30 (23.81)	21 (36.84)	
>90; <40	60 (32.79)	36 (28.57)	24 (42.11)	
Pre-operative organ failure, n (%)				<0.001***
No	111 (60.66)	96 (76.19)	15 (26.32)	
One	39 (21.31)	27 (21.43)	12 (21.05)	
Two or more	33 (18.03)	3 (2.38)	30 (52.63)	
Immuno-compromised status, n (%)				0.252***
No	153 (83.61)	108 (85.71)	45 (78.95)	
Yes	30 (16.39)	18 (14.29)	12 (21.05)	
TNM stage, n (%)				<0.001***
0; I; II	78 (42.62)	69 (54.76)	9 (15.79)	
III; IV	105 (57.38)	57 (45.24)	48 (84.21)	

\*IAS: intra-abdominal sepsis, \*\*PPU: Perforated peptic ulcer, \*\*\* $\chi^2$  test

were left out of the multivariate model. Multiple adjusted analysis indicated ASA score III-IV vs I-II (OR 5.99, 95% CI 2.86 - 12.57,  $p < 0.001$ ) and TNM stage III-IV vs 0-I-II (OR 4.49, 95% CI 1.93 - 10.44,  $p < 0.001$ ) as independent predictors of death in patients with duodenal or gastric ulcer (table 5). The model has a good predictive power being the area under the ROC


curve equal to 0.8058 (standard error 0.0342) (fig. 1).

In the control group retrospectively analysed death occurred in 33.3% of patients, with no significant difference from the study group. The mortality increased among stages (13.1% at stage II, 28.5% at stage III and 100% at stage IV).

**Table 5 - Multiple adjusted analysis between death for PPU\* and independent variables present in the final model**

Prognostic factors	OR <sup>o</sup>	95% CI	p-value
ASA score, n (%)			
I, II <sup>a</sup>	1		
III, IV	5.99	2.86 - 12.57	<0.001
TNM stage, n (%)			
0; I; II <sup>a</sup>	1		
III; IV	4.49	1.93 - 10.44	<0.001

\*PPU: perforated peptic ulcer, <sup>a</sup>reference category, <sup>o</sup>adjusted odds ratios for the other variables in the model



**Figure 1 - Receiver operating characteristics (ROC) curve for model fit. Area under curve (AUC)=0.8058; standard error (SE)=0.0342**

## DISCUSSION

Mortality is a serious complication in PPU. PPU carries a mortality ranging from 1.3% to 40% (4-9,21, 22). The mortality rate is as high as 12%-47% in elderly patients undergoing PPU surgery (23-25). Significant risk factors that lead to death are presence of patients factors (age > 65 years-old, female, underweight, presence of comorbidities, delay in presentation more than 24h, non-steroidal anti-inflammatory or steroid use), disease factors (shock at presentation, elevated urea or creatinine, metabolic acidosis, anemia, hypoalbuminemia), and treatment factors (resection surgery, blood transfusion, intensive care units) (26-33). Several different scoring systems used to predict outcome in PPU can be identified through the literature: the Boey score, the ASA score, the Sepsis score (SS), the Charlson Comorbidity Index (CCI), the Mannheim Peritonitis Index (MPI), the Acute Physiology and Chronic Health Evaluation II (APACHE II), the Simplified Acute Physiology score II (SAPS II), the Physiology and Operative Severity Score for the Enumeration of Mortality and Morbidity Physical Sub-score (POSSUM-phys score), the Mortality Probability Models II (MPM II), the PULP score, the Hacettepe score (HS), the Jabalpur score (JS), the Practical Scoring System of Mortality in Patients with Perforated Peptic Ulcer (POMPPP) score, and the American Association for the Surgery of Trauma (AAST) Emergency General Surgical (EGS) grading system (AAST EGS grade) (34-37). Anbalakan K. et al have validated ASA score, Boey's score, MPI and PULP score and found that all the four systems have moderate accuracy of predicting mortality

with area under the receiver operator curve of 72%-77.2% (37). Other scoring systems are not widely used due a lack of validation or their complexity in clinical use. Our new scoring system (18,19) is simple to use and it seems to be a good predictor of mortality. We believe that the initial TNM stage can be easily adopted in the clinical practice to predict the surgical mortality of PPU patients. Early detection of patients at higher risk could be useful to choose other treatment strategies except surgery to decrease the risk of mortality. More consistent and careful perioperative cares should be adopted, among which respiratory support, circulatory stabilization and frequent monitoring (12,38). To early stage patients, a simple grading system may provide reduction in mortality rates.

The death rates related to complicated IAS is reported to be about 1% (39), 6.7% (40) up to 60% (41-50). The most important variable to explain the difference could be the heterogeneous population of patients and procedures (41,43,51-62). Both the anatomic source of infections and the physiologic impairment affect the outcome (63-67). In our present study we selected a homogeneous sample with the same diagnosis (complicated peptic ulcer), same operation (urgent open repair), same surgical incision (midline laparotomy).

Our results showed that TNM could help to classify patients based on their mortality risk. Moreover, some variables seem to be related to mortality: TNM stages III-IV, ASA score III-IV, neutrophil count and preoperative organ failure. Multivariate analysis, in fact, showed that TNM stage IV and ASA score IV themselves significantly influenced the mortality. Indeed, 90.9% (30/33) of the patients at stage IV died, and the high mortality rate (100%) for M2 patients was mainly reported for patients in the first period of the study (retrospective analysis), when treatment was still not so aggressive as in the last cases considered.

Our grading systems is simple and it allows a re-evaluation of the patients based on the clinical picture.

Some limitations have to be underlined. The prolonged period of data collection and the small sample size are the main ones, because these factors may influence the evaluation of the TNM. Indeed, our study population was only 183 patients, but this number was noticeable when compared with other studies in the literature (6,68-75), except cohort study of Møller 12 and the study of Hernandez (36).

A large-scale clinical trial should be evaluated.

## CONCLUSION

In our preliminary study, we want to describe our results about the use of TNM score to assess IAS after PPU. This “transfer” of TNM from cancer pathology to septic pathology could prove, if other studies confirm our results, to be extremely effective to define the mortality risk in patients with IAS after PPU.

### *Supported and conflict of interest statement*

The authors declare no dedicated source of funding and no conflicts of interest related to this publication.

### *Ethics approval and consent to participate*

This is an observational clinical study, so ethics approval is not required. Informed consent was obtained from all individual participants included in the study.

### *Competing interests*

The authors declare that they have no conflict of interest.

### *Funding: No funding.*

### *Authors' contributions*

M.S. and F.C. provided study conception and design. B.P., L.R., A.G. have acquired the data. A.M. analysed and interpreted these data. L.R. drafted the manuscript. All authors revised, read and approved the final manuscript.

## REFERENCES

1. Testini M, Portincasa P, Piccinni G, Lissidini G, Pellegrini F, Greco L. Significant factors associated with fatal outcome in emergency open surgery for perforated peptic ulcer. *World J Gastroenterol.* 2003; 9(10):2338-40.
2. Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, Krstic M. Complications of peptic ulcer disease. *Dig Dis* 2011; 29(5):491-493.
3. Beatrice P, Lucia R, Antonio G, Domenico G, Mario S, Francesco C, et al. Rare case of upper gastrointestinal bleeding: Dieulafoy's lesion of duodenum. A case report. *Ann Med Surg (Lond).* 2019; 45:19-21.
4. Christensen S, Riis A, Norgaard M, Sørensen HT, Thomsen RW. Short-term mortality after perforated or bleeding peptic ulcer among elderly patients: a population-based cohort study. *BMC Geriatr* 2007; 7:8.
5. Christiansen C, Christensen S, Riis A, Thomsen RW, Johnsen SP, Tonnesen E, et al. Antipsychotic drugs and short-term mortality after peptic ulcer perforation: a population-based cohort study. *Aliment Pharmacol Ther* 2008;28(7):895-902.
6. Thorsen K, Glomsaker TB, von Meer A, Soreide K, Soreide JA.

7. Trends in diagnosis and surgical management of patients with perforated peptic ulcer. *J Gastrointest Surg* 2011;15(8):1329-1335.
8. Bertleff MJ, Lange JF. Perforated peptic ulcer disease: a review of history and treatment. *Dig Surg* 2010;27(3):161-169.
9. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. *Digestion* 2011;84(2):102-113.
10. Bae S, Shim KN, Kim N, Kang JM, Kim DS, Kim KM, et al. Incidence and short-term mortality from perforated peptic ulcer in Korea: a population-based study. *J Epidemiol* 2012;22(6):508-516.
11. Moller MH, Shah K, Bendix J, Jensen AG, Zimmermann-Nielsen E, Adamsen S, et al. Risk factors in patients surgically treated for peptic ulcer perforation. *Scand J Gastroenterol* 2009; 44(2):145-152.
12. Moller MH, Adamsen S, Thomsen RW, Moller AM. Multicentre trial of a perioperative protocol to reduce mortality in patients with peptic ulcer perforation. *Br J Surg* 2011; 98(6):802-810.
13. Møller MH, Engebjerg MC, Adamsen S, Bendix J, Thomsen RW. The Peptic Ulcer Perforation (PULP) score: a predictor of mortality following peptic ulcer perforation. A cohort study. *Acta Anaesthesiol Scand.* 2012; 56:655-62.
14. Boey J, Choi SK, Poon A, Alagaratnam TT. Risk stratification in perforated duodenal ulcers. A prospective validation of predictive factors. *Ann Surg* 1987;205:22-6.
15. Mäkelä JT, Kiviniemi H, Ohtonen P, Laitinen SO. Factors that predict morbidity and mortality in patients with perforated peptic ulcers. *Eur J Surg* 2002;168:446-51.
16. Thorsen K, Søreide JA, Søreide K. Scoring systems for outcome prediction in patients with perforated peptic ulcer. *Scand J Trauma Resusc Emerg Med* 2013;21:25.
17. Thorsen K, Søreide JA, Søreide K. What is the best predictor of mortality in perforated peptic ulcer disease? A population-based, multivariable regression analysis including three clinical scoring systems. *J Gastrointest Surg* 2014;18:1261-8.
18. Mishra A, Sharma D, Raina VK. A simplified prognostic scoring system for peptic ulcer perforation in developing countries. *Indian J Gastroenterol* 2003;22:49-53.
19. Schietroma M, Pessia B, Mattei A, Romano L, Giuliani A, Carlei F. Temperature-Neutrophils-Multiple Organ Failure Grading for Complicated Intra-Abdominal Infections. *Surg Infect (Larchmt)* 2020;21:69-74.
20. Schietroma M, Romano L, Pessia B, Mattei A, Fiasca F, Carlei F, et al. TNM: a simple classification system for complicated intra-abdominal sepsis after acute appendicitis [published online ahead of print, 2020 Aug 6]. *Minerva Chir.* 2020;10.23736/S0026-4733.20.08274-7.
21. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G; STROCCS Group. STROCCS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. *Int J Surg* 2019;72:156-165.
22. Hermansson M, Staël von Holstein C, Zilling T. Surgical approach and prognostic factors after peptic ulcer perforation. *Eur J Surg* 1999; 165: 566-572.
23. Rajesh V, Chandra SS, Smile SR. Risk factors predicting operative mortality in perforated peptic ulcer disease. *Trop Gastroenterol* 2003; 24: 148-150.
24. Blomgren LG. Perforated peptic ulcer: long-term results after simple closure in the elderly. *World J Surg* 1997; 21:412-414.
25. Svanes C, Salvesen H, Stangeland L, Svanes K, Søreide O. Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics. *Gut* 1993; 34:1666-1671.
26. Bulut OB, Rasmussen C, Fischer A. Acute surgical treatment of complicated peptic ulcers with special reference to the elderly. *World J Surg* 1996; 20: 574-577.
27. Buck DL, Møller MH. Influence of body mass index on mortality after surgery for perforated peptic ulcer. *Br J Surg* 2014; 101: 993-999.
28. Nogueira C, Silva AS, Santos JN, Silva AG, Ferreira J, Matos E, et al. Perforated peptic ulcer: main factors of morbidity and mortality. *World J Surg* 2003; 27:782-787.
29. Agrez MV, Henry DA, Senthiselvan S, Duggan JM. Changing trends in perforated peptic ulcer during the past 45 years. *Aust N Z J Surg* 1992; 62:729-732.

29. Svanes C, Lie RT, Lie SA, Kvåle G, Svanes K, Søreide O. Survival after peptic ulcer perforation: a time trend analysis. *J Clin Epidemiol* 1996; 49:1363-1371.
30. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. *Lancet* 1986; 1: 489-492.
31. Kocer B, Surmeli S, Solak C, Unal B, Bozkurt B, Yildirim O, et al. Factors affecting mortality and morbidity in patients with peptic ulcer perforation. *J Gastroenterol Hepatol* 2007;22:565-570.
32. Schietroma M, Colozzi S, Romano L, Pessia B, Giuliani A, Vicentini V, et al. Short- and long-term results after laparoscopic floppy Nissen fundoplication in elderly versus non-elderly patients. *J Minim Access Surg*. 2020;16(3):256-263.
33. Giuliani A, Romano L, Papale E, Puccia I, Di Furia M, Salvatorelli A, et al. Complications of postlaparoscopic sleeve gastric resection: review of surgical technique. *Minerva Chir*. 2019 Jun;74(3):213-217.
34. Knudsen NV, Møller MH. Association of mortality with out-of-hours admission in patients with perforated peptic ulcer. *Acta Anaesthesiol Scand* 2015; 59: 248-254.
35. Menekse E, Kocer B, Topcu R, Olmez A, Tez M, Kayaalp C. A practical scoring system to predict mortality in patients with perforated peptic ulcer. *World J Emerg Surg* 2015 Feb 21;10:7.
36. Hernandez MC, Thorn MJ, Kong VY, Aho JM, Jenkins DH, Bruce JL, et al. Validation of the AAST EGS grading system for perforated peptic ulcer disease. *Surgery* 2018;164(4):738-745.
37. Anbalakan K, Chua D, Pandya GJ, Shelat VG. Five year experience in management of perforated peptic ulcer and validation of common mortality risk prediction models - are existing models sufficient? A retrospective cohort study. *Int J Surg* 2015; 14: 38-44.
38. Møller MH, Adamsen S, Thomsen RW, Møller AM. Peptic Ulcer Perforation (PULP) trial group. Multicentre trial of a perioperative protocol to reduce mortality in patients with peptic ulcer perforation. *Br J Surg*. 2011;98:802-10.
39. Teichmann W, Wittmann DH, Andreone PA. Scheduled reoperations (etappenlavage) for diffuse peritonitis. *Arch Surg* 1986;121: 147-52.
40. Penninckx FM, Kerremans RP, Lauwers PM. Planned relaparotomies in the surgical treatment of severe generalized peritonitis from intestinal origin. *World J Surg* 1983;7:762-6.
41. Biondo S, Ramos E, Fraccalvieri D, Kreisler E, Ragué JM, Jaurrieta E. Comparative study of left colonic Peritonitis Severity Score and Mannheim Peritonitis Index. *Br J Surg*. 2006;93(5):616-22.
42. Schietroma M, Cappelli S, Carlei F, Pescosolido A, Lygidakis NJ, Amicucci G. "Acute abdomen": early laparoscopy or active laparotomic-laparoscopic observation? *Hepatogastroenterology* 2007; 54(76):1137-41.
43. Kologlu M, Elker D, Altun H, Sayek I. Validation of MPI and PIA II in two different groups of patients with secondary peritonitis. *Hepatogastroenterology* 2001;48(37):147-51.
44. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intra-abdominal infection. *N Engl J Med* 2015;372: 1996-2005.
45. Schein M, Decker GA. The Hartmann procedure: extended indications in severe intra-abdominal infection. *Dis Colon Rectum* 1988;31:126-9.
46. Schietroma M, Cecilia EM, De Santis G, Carlei F, Pessia B, Amicucci G. Supplemental Peri-Operative Oxygen and Incision Site Infection after Surgery for Perforated Peptic Ulcer: A Randomized, Double-Blind Monocentric Trial. *Surg Infect (Larchmt)* 2016;17(1):106-13.
47. Marchese M, Romano L, Giuliani A, Cianca G, Di Sibio A, Carlei F, et al. A case of intrasplenic displacement of an endoscopic double-pigtail stent as a treatment for laparoscopic sleeve gastrectomy leak [published correction appears in *Int J Surg Case Rep*. 2019;56:49]. *Int J Surg Case Rep*. 2018;53:367-369.
48. Giuliani A, Romano L, Marchese M, Necozone S, Cianca G, Schietroma M, et al. Gastric leak after laparoscopic sleeve gastrectomy: management with endoscopic double pigtail drainage. A systematic review. *Surg Obes Relat Dis* 2019;15(8):1414-1419.
49. Schietroma M, Pessia B, Carlei F, Amicucci G. Septic complications after pancreatoduodenectomy for pancreatic adenocarcinoma: are increased gut permeability and inflammatory serum markers responsible? *Pancreas* 2016;45(9):e47-8.
50. Schein M, Saadia R, Freinkel Z, Decker GA. Aggressive treatment of severe diffuse peritonitis: a prospective study. *Br J Surg* 1988;75: 173-6.
51. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE –acute physiology and chronic health evaluation: a physiologically based classification system. *Crit Care Med* 1981; 9: 591-7.
52. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1985;13: 818-29.
53. Le Gall J-R, Loirat P, Alperovitch A. Simplified acute physiological score for intensive care patients. *Lancet* 1983; ii: 741.
54. Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, et al. A simplified acute physiology score for ICU patients. *Crit Care Med* 1984;12: 975-7.
55. Elebute EA, Stoner HB. The grading of sepsis. *Br J Surg* 1983; 70: 29-31.
56. Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrère JS. Multiple-organ failure: generalized autodestructive inflammation? *Arch Surg* 1985; 120: 1109-15.
57. Muralidhar V A, Madhu CP, Sudhir S, Madhu S. Mannheim peritonitis index –prediction of risk of death from peritonitis: construction of a statistical and validation of an empirically based index. *Theoretical Surgery* 1987;1: 169-77.
58. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. *Br J Surg* 1978;65: 337-41.
59. Bosscha K, Reijnders K, Hulstaer PF, Algra A, van der Werken C. Prognostic scoring system to predict outcome in peritonitis and intra-abdominal sepsis. *BJS* 1997;84:1532-4.
60. Sartelli M, Abu-Zidan FM, Catena F, Griffiths EA, Di Saverio S, et al. Global validation of the WSES Sepsis Severity Score for patients with complicated intra-abdominal infections: a prospective multicentre study (WISS Study). *World J Emerg Surg* 2015;10:61.
61. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. *Chest* 1991; 100:1619-36.
62. Prytherch DR, Whiteley MS, Higgins B, Weaver PC, Prout WG, Powell SJ. POSSUM and Portsmouth-POSSUM for predicting mortality. *Br J Surg*. 1998; 85: 1217-1220.
63. Bohnen J, Boulanger M, Meakins JL, McLean AP. Prognosis in generalized peritonitis. Relation to cause and risk factors. *Arch Surg*. 1983;118(3):285-290.
64. Meakins JL, Solomkin JS, Allo MD, Dellinger EP, Howard RJ, Simmons RL. A proposed classification of intra-abdominal infections. Stratification of etiology and risk for future therapeutic trials. *Arch Surg* 1984;119(12):1372-1378.
65. Dellinger EP, Wertz MJ, Meakins JL, Solomkin JS, Allo MD, Howard RJ, et al. Surgical infection stratification system for intra-abdominal infection. Multicenter trial. *Arch Surg* 1985;120(1):21-29.
66. Giuliani A, Romano L, Coletti G, Walid A, Fatayer M, Calvisi G, Maffione F, et al. Lymphangiomatosis of the ileum with perforation: A case report and review of the literature. *Ann Med Surg (Lond)* 2019;41:6-10.
67. Giuliani A, Romano L, Papale E, et al. Post-surgical abdominal damage: management and treatment with vacuum therapy and biological mesh. *Chirurgia* 2019;32:275-9.
68. Arici C, Mesci A, Dincer D, Dinckan A, Colak T. Analysis of risk factors predicting (affecting) mortality and morbidity of peptic ulcer perforations. *Int Surg* 2007; 92(3):147-154.
69. Forsmo HM, Glomsaker T, Vandvik PO. Perforated peptic ulcer - a 12-year material. *Tidsskr Nor Laegeforen* 2005; 125(13): 1822-1824.

70. Kim JM, Jeong SH, Lee YJ, Park ST, Choi SK, Hong SC, et al. Analysis of risk factors for postoperative morbidity in perforated peptic ulcer. *Journal of gastric cancer* 2012; 12(1):26–35.
71. Kujath P, Schwandner O, Bruch HP. Morbidity and mortality of perforated peptic gastroduodenal ulcer following emergency surgery. *Langenbecks Arch Surg* 2002; 387(7–8):298–302.
72. Lohsiriwat V, Prapasrivorakul S, Lohsiriwat D. Perforated peptic ulcer: clinical presentation, surgical outcomes, and the accuracy of the Boey scoring system in predicting postoperative morbidity and mortality. *World J Surg* 2009; 33(1):80–85.
73. Mishra A, Sharma D, Raina VK. A simplified prognostic scoring system for peptic ulcer perforation in developing countries. *Indian J Gastroenterol* 2003; 22(2):49–53.
74. Rajesh V, Chandra SS, Smile SR. Risk factors predicting operative mortality in perforated peptic ulcer disease. *Trop Gastroenterol* 2003; 24(3):148–150.
75. Buck DL, Vester-Andersen M, Møller MH. Accuracy of clinical prediction rules in peptic ulcer perforation: an observational study. *Scand J Gastroenterol* 2012;47(1):28–35.